Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.45 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491587 | 0.94 | FKBP1A (0.54) | FKBP1ATSHRALDH1A1MMP1MMP13 | |
| SCHEMBL5495223 | 0.94 | FKBP1A (0.54) | FKBP1ATSHRALDH1A1MMP1MMP13 | |
| SCHEMBL5494189 | 0.86 | FKBP1A (0.67) | FKBP1AITGA4ITGB1ITGA2MAPK1 | |
| SCHEMBL6401233 | 0.85 | ITGB1 (0.58) | FKBP1ATSHRMMP1MMP13MMP9 | |
| SCHEMBL6151068 | 0.85 | ITGB1 (0.58) | FKBP1ATSHRMMP1MMP13MMP9 | |
| SCHEMBL7317563 | 0.83 | ITGB1 (0.63) | TSHRALDH1A1ITGA4ITGB1ITGA2 | |
| SCHEMBL5497980 | 0.83 | FKBP1A (0.58) | FKBP1ATSHRITGA4ITGB1ITGA2 | |
| SCHEMBL5499020 | 0.82 | ITGA4 (0.56) | FKBP1ATSHRMMP9ITGA4ITGB1 | |
| SCHEMBL5491585 | 0.82 | FKBP1A (0.53) | FKBP1AITGA4ITGB1ITGA2MAPK1 | |
| SCHEMBL5487316 | 0.81 | FKBP1A (0.61) | FKBP1AMMP1MMP13MMP9ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | claimed |
| US-6423688-B1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ATHENA NEUROSCIENCES, INC. | 2002-07-23 | — | — | US | claimed |
| EP-1001971-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999006432-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-7288526-B2 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | disclosed |
| US-6423688-B1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ATHENA NEUROSCIENCES, INC. | 2002-07-23 | — | — | US | disclosed |
| EP-1001971-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006432-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, IL4I1 | FKBP1A 4722/4885TSHR 4038/4885ALDH1A1 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.